TAMPA, Fla., March 3 /PRNewswire/ -- MiMedx, Inc., a development-stage medical device company, announced today that Brian J. Splan has been appointed President. In this role, Mr. Splan will be providing strategic and tactical leadership to the MiMedx team.
Throughout his 34-year career, Mr. Splan has consistently demonstrated the ability to manage a wide range of operations and deliver excellent results for customers and shareholders. Beginning in 1986, Mr. Splan was employed by Smith & Nephew, Inc. in a variety of positions of increasing responsibility. Mr. Splan was Executive Vice President of Finance and Administration of Smith & Nephew, Inc., President of Ioptex Research, Inc., a subsidiary of Smith & Nephew, PLC. He also served as President of the Healthcare Division of Smith & Nephew, Inc. US operations.
“We are delighted to have the opportunity to add someone of Brian’s caliber to our senior management team,” said Tom D’Alonzo, CEO of MiMedx. “His extensive experience will help us to accelerate our exciting discoveries into product candidates.”
MiMedx recently became a public Company through a reverse merger with Alynx, Co. For more information on MiMedx, see www.mimedx.com.
About MiMedx, Inc.
Founded in 2006, MiMedx, Inc. is a development-stage Florida corporation with technology focusing on biomaterials for soft tissue repair, such as tendons, ligaments and cartilage, as well as other biomaterial-based products for other medical applications. The company, based in Tampa, Florida, holds an exclusive, worldwide license from the Shriner’s Hospital for Children and the University of South Florida Research Foundation for certain nordihydroguaiaretic acid (NDGA) technology. MiMedx is targeting this proprietary technology for a number of diverse medical applications.
MiMedx, Inc. also has a wholly-owned subsidiary, SpineMedica, LLC, based in Atlanta, Georgia, led by an industry veteran, R. Lewis Bennett. MiMedx completed an acquisition of SpineMedica Corp., in July, 2007. SpineMedica, a Florida limited liability company, is a development-stage company focusing on the commercialization of medical device technologies for application in the spine and chronic back pain. SpineMedica’s goal is to acquire promising technologies in this field through licensing arrangements and develop and commercialize such technologies.
For further information, please refer to the Form 8-K to be filed by Alynx with the SEC as soon as practicable after the merger. When filed, the Form 8- K will be accessible at: http://www.sec.gov/edgar/searchedgar/companysearch.html by inserting “Alynx” in the “company name” search line.
This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements may be identified by their use of terms or phrases such as “expects,” “estimates,” “projects,” “believes,” “anticipates,” “plans,” “intends,” and similar terms and phrases. Forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. For example, MiMedx and SpineMedica may be unable to continue their efforts on particular products due to future laboratory results. We disclaim any obligation to update or revise any forward-looking statements to reflect actual results or changes in the factors affecting the forward-looking information.
CONTACT: Matthew J. Miller, Executive Vice President of Alynx,
+1-813-866-0000
Web site: http://www.mimedx.com/
http://www.sec.gov/edgar/searchedgar/companysearch.html/
